Welcome to our dedicated page for Greater Cannabis Company SEC filings (Ticker: GCAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Greater Cannabis Company's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Greater Cannabis Company's regulatory disclosures and financial reporting.
The Greater Cannabis Company (GCAN) is implementing a 1-for-1,500 reverse stock split of its common stock, effective as of the close of business on October 15, 2025. The stock will begin trading on a post-split basis on October 16, 2025 under the temporary ticker GCAND for twenty trading days, with a new CUSIP 391657202.
The reverse split reduces issued and outstanding common shares from 1,349,888,436 to approximately 900,256. No fractional shares will be issued; holders entitled to a fraction will receive one whole share. The action also applies to shares issuable upon conversion of outstanding convertible debt, warrants, and options. Authorized shares and par value ($0.001) remain unchanged, and the company notes it will have additional shares available for potential future issuance, without specific plans beyond honoring existing convertible and equity awards.